Literature DB >> 12594806

A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?

Keiran S M Smalley1.   

Abstract

During the process of oncogenic transformation, melanoma cells escape from normal growth-control mechanisms and acquire the ability to invade surrounding tissues and organs. The Ras/Raf/MEK/ERK pathway is a major pathway involved in the control of growth signals, cell survival and invasion. Melanomas are known to harbour activating mutations of both Ras and BRAF, suggesting that the downstream effector ERK may be playing a major role in the oncogenic behaviour of these tumours. The past few years have seen a growth in the understanding of the role of ERK and the MAP kinase pathway in melanoma. The aim of the current review is to assess the role of ERK in melanoma behaviour and to determine whether modulation of these kinases could offer new therapeutic opportunities. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594806     DOI: 10.1002/ijc.10978

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  95 in total

Review 1.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Authors:  Inna V Fedorenko; Kim H T Paraiso; Keiran S M Smalley
Journal:  Biochem Pharmacol       Date:  2011-05-25       Impact factor: 5.858

2.  Β-elemene inhibits Hsp90/Raf-1 molecular complex inducing apoptosis of glioblastoma cells.

Authors:  Yong-Shun Zhao; Ting-Zhun Zhu; Yan-Wei Chen; Yi-Qun Yao; Chun-Ming Wu; Zhen-Qing Wei; Wei Wang; Ying-Hui Xu
Journal:  J Neurooncol       Date:  2011-12-11       Impact factor: 4.130

Review 3.  Modulation of protein kinase signaling cascades by palytoxin.

Authors:  Elizabeth V Wattenberg
Journal:  Toxicon       Date:  2010-11-09       Impact factor: 3.033

4.  Comparison of Xiphophorus and human melanoma transcriptomes reveals conserved pathway interactions.

Authors:  Yuan Lu; Mikki Boswell; William Boswell; Susanne Kneitz; Michael Hausmann; Barbara Klotz; Janine Regneri; Markita Savage; Angel Amores; John Postlethwait; Wesley Warren; Manfred Schartl; Ronald Walter
Journal:  Pigment Cell Melanoma Res       Date:  2018-01-29       Impact factor: 4.693

5.  Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines.

Authors:  Kim H T Paraiso; Kaisa Van Der Kooi; Jane L Messina; Keiran S M Smalley
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

6.  Mechanisms involved in ceramide-induced cell cycle arrest in human hepatocarcinoma cells.

Authors:  Jing Wang; Xiao-Wen Lv; Jie-Ping Shi; Xiao-Song Hu
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

7.  Functional erythropoietin autocrine loop in melanoma.

Authors:  Suresh M Kumar; Geza Acs; Dong Fang; Meenhard Herlyn; David E Elder; Xiaowei Xu
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.

Authors:  Seema Singh; Anguraj Sadanandam; Kalyan C Nannuru; Michelle L Varney; Rosemary Mayer-Ezell; Richard Bond; Rakesh K Singh
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

9.  NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma.

Authors:  Deon G Uffort; Elizabeth A Grimm; Julie A Ellerhorst
Journal:  J Invest Dermatol       Date:  2008-07-31       Impact factor: 8.551

Review 10.  The role of altered cell-cell communication in melanoma progression.

Authors:  Nikolas K Haass; Keiran S M Smalley; Meenhard Herlyn
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.